obeticholic-acid and Atherosclerosis

obeticholic-acid has been researched along with Atherosclerosis* in 2 studies

Reviews

1 review(s) available for obeticholic-acid and Atherosclerosis

ArticleYear
Use of farnesoid X receptor agonists to treat nonalcoholic fatty liver disease.
    Digestive diseases (Basel, Switzerland), 2015, Volume: 33, Issue:3

    Nonalcoholic fatty liver disease is a common cause of liver related morbidity and mortality. It is closely linked to underlying insulin resistance. It has recently been shown that bile acids modulate insulin signaling and can improve insulin resistance in cell based and animal studies. These effects are mediated in part by activation of farnesoid x receptors by bile acids. In human studies, FXR agonists improve insulin resistance and have recently been shown to improve NAFLD. The basis for the use of FXR agonists for the treatment of NAFLD and early human experience with such agents is reviewed in this paper.

    Topics: Animals; Atherosclerosis; Chenodeoxycholic Acid; Humans; Insulin Resistance; Lipid Metabolism; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear

2015

Other Studies

1 other study(ies) available for obeticholic-acid and Atherosclerosis

ArticleYear
A Translational Mouse Model for NASH with Advanced Fibrosis and Atherosclerosis Expressing Key Pathways of Human Pathology.
    Cells, 2020, 09-01, Volume: 9, Issue:9

    Non-alcoholic steatohepatitis (NASH) is a fast-growing liver disorder that is associated with an increased incidence of cardiovascular disease and type 2 diabetes. Animal models adequately mimicking this condition are scarce. We herein investigate whether Ldlr-/-. Leiden mice on different high-fat diets represent a suitable NASH model. Ldlr-/-. Leiden mice were fed a healthy chow diet or fed a high-fat diet (HFD) containing lard or a fast food diet (FFD) containing milk fat. Additionally, the response to treatment with obeticholic acid (OCA) was evaluated. Both high-fat diets induced obesity, hyperlipidemia, hyperinsulinemia, and increased alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels. Mice on both diets developed progressive macro- and microvesicular steatosis, hepatic inflammation, and fibrosis, along with atherosclerosis. HFD induced more severe hyperinsulinemia, while FFD induced more severe hepatic inflammation with advanced (F3) bridging fibrosis, as well as more severe atherosclerosis. OCA treatment significantly reduced hepatic inflammation and fibrosis, and it did not affect atherosclerosis. Hepatic transcriptome analysis was compared with human NASH and illustrated similarity. The present study defines a translational model of NASH with progressive liver fibrosis and simultaneous atherosclerosis development. By adaptation of the fat content of the diet, either insulin resistance (HFD) or hepatic inflammation and fibrosis (FFD) can be aggravated.

    Topics: Animals; Atherosclerosis; Chenodeoxycholic Acid; Diet, High-Fat; Disease Models, Animal; Fast Foods; Hyperinsulinism; Hyperlipidemias; Liver Cirrhosis; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Non-alcoholic Fatty Liver Disease; Obesity; Receptors, LDL; Transcriptome; Treatment Outcome

2020